Centanafadine emerges as a triple-action ADHD treatment with potential for patients with anxiety

A new ADHD medication, centanafadine, stands out as the first to simultaneously target dopamine, norepinephrine, and serotonin, offering a novel approach that may benefit patients unresponsive to existing treatments, with ongoing assessments of its safety and regulatory status worldwide. Centanafadine,…















